76 related articles for article (PubMed ID: 24769691)
1. In silico design of small molecule inhibitors of CDK9/cyclin T1 interaction.
Randjelovic J; Eric S; Savic V
J Mol Graph Model; 2014 May; 50():100-12. PubMed ID: 24769691
[TBL] [Abstract][Full Text] [Related]
2. Computational study and peptide inhibitors design for the CDK9 - cyclin T1 complex.
Randjelović J; Erić S; Savić V
J Mol Model; 2013 Apr; 19(4):1711-25. PubMed ID: 23296566
[TBL] [Abstract][Full Text] [Related]
3. The CDK9-cyclin T1 complex mediates saturated fatty acid-induced vascular calcification by inducing expression of the transcription factor CHOP.
Shiozaki Y; Okamura K; Kohno S; Keenan AL; Williams K; Zhao X; Chick WS; Miyazaki-Anzai S; Miyazaki M
J Biol Chem; 2018 Nov; 293(44):17008-17020. PubMed ID: 30209133
[TBL] [Abstract][Full Text] [Related]
4. The role of the Cdk9/Cyclin T1 complex in T cell differentiation.
Leucci E; De Falco G; Onnis A; Cerino G; Cocco M; Luzzi A; Crupi D; Tigli C; Bellan C; Tosi P; Leoncini L; Giordano A
J Cell Physiol; 2007 Aug; 212(2):411-5. PubMed ID: 17352406
[TBL] [Abstract][Full Text] [Related]
5. Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral pUL69 and cyclin T1.
Feichtinger S; Stamminger T; Müller R; Graf L; Klebl B; Eickhoff J; Marschall M
J Gen Virol; 2011 Jul; 92(Pt 7):1519-1531. PubMed ID: 21450947
[TBL] [Abstract][Full Text] [Related]
6. CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation.
Bellan C; De Falco G; Lazzi S; Micheli P; Vicidomini S; Schürfeld K; Amato T; Palumbo A; Bagella L; Sabattini E; Bartolommei S; Hummel M; Pileri S; Tosi P; Leoncini L; Giordano A
J Pathol; 2004 Aug; 203(4):946-52. PubMed ID: 15258998
[TBL] [Abstract][Full Text] [Related]
7. Cdk9/Cyclin T1 complex: a key player during the activation/differentiation process of normal lymphoid B cells.
De Falco G; Leucci E; Onnis A; Bellan C; Tigli C; Wirths S; Cerino G; Cocco M; Crupi D; De Luca A; Lanzavecchia A; Tosi P; Leoncini L; Giordano A
J Cell Physiol; 2008 Apr; 215(1):276-82. PubMed ID: 18205180
[TBL] [Abstract][Full Text] [Related]
8. Determining the Functions of HIV-1 Tat and a Second Magnesium Ion in the CDK9/Cyclin T1 Complex: A Molecular Dynamics Simulation Study.
Jin HX; Go ML; Yin P; Qiu XT; Zhu P; Yan XJ
PLoS One; 2015; 10(4):e0124673. PubMed ID: 25909811
[TBL] [Abstract][Full Text] [Related]
9. MD simulation of the Tat/Cyclin T1/CDK9 complex revealing the hidden catalytic cavity within the CDK9 molecule upon Tat binding.
Asamitsu K; Hirokawa T; Okamoto T
PLoS One; 2017; 12(2):e0171727. PubMed ID: 28178316
[TBL] [Abstract][Full Text] [Related]
10. Ligand- and structure-based pharmacophore modeling, docking study reveals 2-[[4-[6-(isopropylamino) pyrimidin-4-yl]-1H-pyrrolo[2,3-b] pyridin-6-yl] amino] ethanol as a potential anticancer agent of CDK9/cyclin T1 kinase.
Hussain A; Verma CK
J Cancer Res Ther; 2019; 15(5):1131-1140. PubMed ID: 31603123
[TBL] [Abstract][Full Text] [Related]
11. Cyclin T1 domains involved in complex formation with Tat and TAR RNA are critical for tat-activation.
Ivanov D; Kwak YT; Nee E; Guo J; García-Martínez LF; Gaynor RB
J Mol Biol; 1999 Apr; 288(1):41-56. PubMed ID: 10329125
[TBL] [Abstract][Full Text] [Related]
12. Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure.
Sano M; Wang SC; Shirai M; Scaglia F; Xie M; Sakai S; Tanaka T; Kulkarni PA; Barger PM; Youker KA; Taffet GE; Hamamori Y; Michael LH; Craigen WJ; Schneider MD
EMBO J; 2004 Sep; 23(17):3559-69. PubMed ID: 15297879
[TBL] [Abstract][Full Text] [Related]
13. The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508.
Baumli S; Hole AJ; Noble ME; Endicott JA
ACS Chem Biol; 2012 May; 7(5):811-6. PubMed ID: 22292676
[TBL] [Abstract][Full Text] [Related]
14. Preventing the formation of positive transcription elongation factor b by human cyclin T1-binding RNA aptamer for anti-HIV transcription.
Um HJ; Kim M; Lee SH; Kim YH
AIDS; 2012 Aug; 26(13):1599-605. PubMed ID: 22569018
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol.
de Azevedo WF; Canduri F; da Silveira NJ
Biochem Biophys Res Commun; 2002 Apr; 293(1):566-71. PubMed ID: 12054639
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of novel 4,4'-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer.
Gao G; Li J; Cao Y; Li X; Qian Y; Wang X; Li M; Qiu Y; Wu T; Wang L; Fang M
Eur J Med Chem; 2023 Dec; 261():115858. PubMed ID: 37837671
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of cyclin T1/CDK9 complexes during T cell activation.
Garriga J; Peng J; Parreño M; Price DH; Henderson EE; Graña X
Oncogene; 1998 Dec; 17(24):3093-102. PubMed ID: 9872325
[TBL] [Abstract][Full Text] [Related]
18. Discovery of HyT-Based Degraders of CDK9-Cyclin T1 Complex.
Lin R; Yang J; Liu T; Wang M; Ke C; Luo C; Lin J; Li J; Lin H
Chem Biodivers; 2023 Aug; 20(8):e202300769. PubMed ID: 37349855
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer.
Li J; Liu T; Song Y; Wang M; Liu L; Zhu H; Li Q; Lin J; Jiang H; Chen K; Zhao K; Wang M; Zhou H; Lin H; Luo C
J Med Chem; 2022 Aug; 65(16):11034-11057. PubMed ID: 35925880
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological targeting of CDK9 in cardiac hypertrophy.
Krystof V; Chamrád I; Jorda R; Kohoutek J
Med Res Rev; 2010 Jul; 30(4):646-66. PubMed ID: 19757441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
